Novel blood pressure locus and gene discovery using genome-wide association study and expression data sets from blood and the kidney by Wain, Louise V et al.
  
 
 
 
 
Wain, L. V. et al. (2017) Novel blood pressure locus and gene discovery using genome-
wide association study and expression data sets from blood and the kidney. 
Hypertension, 70(3), e4-e19. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/145382/ 
     
 
 
 
 
 
 
Deposited on: 31 August 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
 
 
 
 
 
 
 
Novel blood pressure locus and gene discovery using GWAS and expression 
datasets from blood and the kidney 
 
 
Louise V. Wain1, Ahmad Vaez2,3, Rick Jansen4, Roby Joehanes5,6, Peter J. van der Most2, A. Mesut 
Erzurumluoglu1, Paul O'Reilly7, Claudia P. Cabrera8,9, Helen R. Warren8,9, Lynda M. Rose10, Germaine 
C. Verwoert11, Jouke-Jan Hottenga12, Rona J. Strawbridge13,14, Tonu Esko15,16,17, Dan E. Arking18, Shih-
Jen Hwang19,20, Xiuqing Guo21, Zoltan Kutalik22,23, Stella Trompet24,25, Nick Shrine1, Alexander 
Teumer26,27, Janina S. Ried28, Joshua C. Bis29, Albert V. Smith30,31, Najaf Amin32, Ilja M. Nolte2, Leo-
Pekka Lyytikäinen33,34, Anubha Mahajan35, Nicholas J. Wareham36, Edith Hofer37,38, Peter K. Joshi39, 
Kati Kristiansson40, Michela Traglia41, Aki S. Havulinna40, Anuj Goel42,35, Mike A. Nalls43,44, Siim 
Sõber45, Dragana Vuckovic46,47, Jian'an Luan36, Fabiola Del Greco M.48, Kristin L. Ayers49, Jaume 
Marrugat50, Daniela Ruggiero51, Lorna M. Lopez52,53,54, Teemu Niiranen40, Stefan Enroth55, Anne U. 
Jackson56, Christopher P. Nelson57,58, Jennifer E. Huffman59, Weihua Zhang60,61, Jonathan Marten62, 
Ilaria Gandin47, Sarah E Harris52,63, Tatijana Zemonik64, Yingchang Lu65, Evangelos Evangelou60,66, Nabi 
Shah67,68, Martin H. de Borst69, Massimo Mangino70,71, Bram P. Prins72, Archie Campbell73,74, Ruifang 
Li-Gao75, Ganesh Chauhan76,77, Christopher Oldmeadow78, Gonçalo Abecasis79, Maryam Abedi80, 
Caterina M. Barbieri41, Michael R. Barnes8,9, Chiara Batini1, John Beilby81,82,83,  BIOS Consortium84, 
Tineka Blake1, Michael Boehnke56, Erwin P. Bottinger65, Peter S. Braund57,58, Morris Brown8,9, Marco 
Brumat47, Harry Campbell39, John C. Chambers60,61,85, Massimiliano Cocca47, Francis Collins86, John 
Connell87, Heather J. Cordell88, Jeffrey J. Damman89, Gail Davies52,90, Eco J. de Geus12, Renée de 
Mutsert75, Joris Deelen91, Yusuf Demirkale92, Alex S.F. Doney67, Marcus Dörr93,27, Martin Farrall42,35, 
Teresa Ferreira35, Mattias Frånberg13,14,94, He Gao60, Vilmantas Giedraitis95, Christian Gieger96, Franco 
Giulianini10, Alan J. Gow52,97, Anders Hamsten13,14, Tamara B. Harris98, Albert Hofman11,99, Elizabeth G. 
Holliday78, Jennie Hui81,82,100,83, Marjo-Riitta Jarvelin101,102,103,104, Åsa Johansson55, Andrew D. 
Johnson6,105, Pekka Jousilahti40, Antti Jula40, Mika Kähönen106,107, Sekar Kathiresan108,109,110, Kay-Tee 
Khaw111, Ivana Kolcic112, Seppo Koskinen40, Claudia Langenberg36, Marty Larson6, Lenore J. Launer98, 
Benjamin Lehne60, David C.M. Liewald52,90,  Lifelines Cohort Study113, Li Lin114, Lars Lind115, François 
Mach114, Chrysovalanto Mamasoula116, Cristina Menni70, Borbala Mifsud8, Yuri Milaneschi117, Anna 
2 
 
Morgan47, Andrew D. Morris118, Alanna C. Morrison119, Peter J. Munson92, Priyanka Nandakumar18, 
Quang Tri Nguyen92, Teresa Nutile51, Albertine J. Oldehinkel120, Ben A. Oostra32, Elin Org15, Sandosh 
Padmanabhan121,74, Aarno Palotie122, Guillaume Paré123, Alison Pattie90, Brenda W.J.H. Penninx117, 
Neil Poulter124, Peter  P. Pramstaller48,125,126, Olli T. Raitakari127,128, Meixia Ren8,129, Kenneth Rice130, 
Paul M. Ridker10,131, Harriëtte Riese120, Samuli Ripatti122, Antonietta Robino132, Jerome I. Rotter133, 
Igor Rudan39, Yasaman Saba134, Aude Saint Pierre48,135, Cinzia F. Sala41, Antti-Pekka Sarin122, Reinhold 
Schmidt37, Rodney Scott78,136,137, Marc A. Seelen69, Denis C. Shields138, David Siscovick139, Rossella 
Sorice51,140, Alice Stanton141, David J. Stott142, Johan Sundström115, Morris Swertz143, Kent D. 
Taylor144,145, Simon Thom146, Ioanna Tzoulaki60, Christophe Tzourio76,77,147, André G. Uitterlinden11,148,  
Understanding Society Scientific group84, Uwe Vöker149,27, Peter Vollenweider150, Sarah Wild39, 
Gonneke Willemsen12, Alan F. Wright62, Jie Yao21, Sébastien Thériault123, David Conen151, Attia 
John78,136,137, Peter Sever152, Stéphanie Debette76,77,153, Dennis O. Mook-Kanamori75,154, Eleftheria 
Zeggini72, Tim D. Spector70, Pim van der Harst155, Colin N.A. Palmer67, Anne-Claire Vergnaud60, Ruth 
J.F. Loos36,156,157, Ozren Polasek112, John M. Starr52,158, Giorgia Girotto47,46, Caroline Hayward159,74, 
Jaspal S. Kooner160,61,85, Cecila M. Lindgren17,35, Veronique Vitart59, Nilesh J. Samani57,58, Jaakko 
Tuomilehto161,162,163,164, Ulf Gyllensten55, Paul Knekt40, Ian J. Deary52,90, Marina Ciullo51,140, Roberto 
Elosua50, Bernard D. Keavney165, Andrew A. Hicks48, Robert A. Scott36, Paolo Gasparini46,47, Maris 
Laan45,166, YongMei Liu167, Hugh Watkins42,35, Catharina A. Hartman120, Veikko Salomaa40, Daniela 
Toniolo41, Markus Perola40,122,168, James F. Wilson39,62, Helena Schmidt134,169, Jing Hua Zhao36, Terho 
Lehtimäki33,34, Cornelia M. van Duijn32, Vilmundur Gudnason30,31, Bruce M. Psaty29,170,171,172, Annette 
Peters28, Rainer Rettig173, Alan James174,175, J Wouter Jukema24, David P. Strachan176, Walter 
Palmas177, Andres Metspalu15, Erik Ingelsson178,179, Dorret I. Boomsma12, Oscar H. Franco11, Murielle 
Bochud22, Christopher Newton-Cheh180,108,110,17, Patricia B. Munroe8,9, Paul Elliott104, Daniel I. 
Chasman10,131, Aravinda Chakravarti18, Joanne Knight181, Andrew P. Morris182,35, Daniel Levy183,20, 
Martin D. Tobin1, Harold Snieder2*, Mark J. Caulfield8,9*, Georg B. Ehret18,114* 
*: contributing equally 
 
Corresponding authors: Louise V. Wain (louisewain@le.ac.uk) and Georg B. Ehret (georg@rhone.ch) 
AFFILIATIONS 
1.   Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK 
2.   Department of Epidemiology, University of Groningen, University Medical Center Groningen, 
Hanzeplein 1, 9713 GZ Groningen, The Netherlands 
3.   Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of 
Medical Sciences, Isfahan, Iran 
3 
 
4.   Department of Psychiatry, VU University Medical Center, Neuroscience Campus Amsterdam, 
Amsterdam, The Netherlands 
5.   Hebrew SeniorLife, Harvard Medical School, 1200 Centre Street Room #609, Boston, MA 02131, 
USA 
6.   National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA 01702, 
USA 
7.   Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK 
8.   Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of 
Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK 
9.   NIHR Barts Cardiovascular Biomedical Research Unit, Barts and The London School of Medicine 
and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK 
10.   Division of Preventive Medicine, Brigham and Women's Hospital, Boston MA 02215, USA 
11.   Department of Epidemiology, Erasmus MC, Rotterdam, 3000CA, The Netherlands 
12.   Department of Biological Psychology, Vrije Universiteit, Amsterdam, EMGO+ institute, VU 
University medical center, Amsterdam, The Netherlands 
13.   Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, 
17176, Sweden 
14.   Centre for Molecular Medicine, Karolinska Universitetsjukhuset, Solna, 171 76, Sweden 
15.   Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia 
16.   Divisions of Endocrinology/Children's Hospital, Boston, MA 02115, USA 
17.   Broad Institute of Harvard and MIT, Cambridge, MA 02139 USA 
18.   Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns 
Hopkins University School of Medicine, Baltimore, MD 21205, USA 
19.   The Population Science Branch, Division of Intramural Research, National Heart Lung and Blood 
Institute national Institute of Health, Bethesda, MD 20892, USA 
20.   The Framingham Heart Study, Framingham MA 01702, USA 
21.   The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, 
LABioMed at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA 
22.   Institute of Social and Preventive Medicine, Lausanne University Hospital, Route de la Corniche 
10, 1010 Lausanne, Switzerland 
23.   Swiss Institute of Bioinformatics, Lausanne, Switzerland 
24.   Department of Cardiology, Leiden University Medical Center, Leiden, 2300RC, The Netherlands 
25.   Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, 2300RC, 
The Netherlands 
26.   Institute for Community Medicine, University Medicine Greifswald, Greifswald, 17475, Germany 
27.   DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald, 17475, 
Germany 
28.   Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg 85764, Germany 
29.   Cardiovascular Health Research Unit, Department of Medicine, University of Washington, 
Seattle, WA 98101, USA 
30.   Icelandic Heart Assoication, Kopavogur, Iceland 
31.   Faculty of Medicine, University of Iceland, Reykjavik, Iceland 
32.   Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC, Rotterdam, 3000CA, The 
Netherlands 
33.   Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland 
4 
 
34.   Department of Clinical Chemistry, Faculty of Medicine and Life Sciences, University of Tampere, 
Tampere 33014, Finland 
35.   Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 
7BN, UK 
36.   MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of 
Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK 
37.   Clinical Division of Neurogeriatrics, Department of Neurology, Medical University Graz, 
Auenbruggerplatz 22, 8036 Graz, Austria 
38.   Institute of Medical Informatics, Statistics and Documentation, Medical University Graz, 
Auenbruggerplatz 2, 8036 Graz, Austria 
39.   Centre for Global Health Research, Usher Institute of Population Health Sciences and 
Informatics, University of Edinburgh EH89AG, Scotland, UK 
40.   Department of Health, National Institute for Health and Welfare (THL), Helsinki, Finland 
41.   Division of Genetics and Cell Biology, San Raffaele Scientific Institute, 20132 Milano, Italy 
42.   Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, 
Oxford, OX3 9DU, UK 
43.   Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, 20892, USA 
44.   Kelly Services, Rockville, MD, USA 
45.   Human Molecular Genetics Research Group, Institute of Molecular and Cell Biology, University 
of Tartu, Riia St.23, 51010 Tartu, Estonia 
46.   Experimental Genetics Division, Sidra Medical and Research Center, PO Box 26999, Doha, Qatar 
47.   Department of Medical, Surgical and Health Sciences, University of Trieste, Strada di Fiume 447, 
Trieste, 34100, Italy 
48.   Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy - Affiliated 
Institute of the University of Lübeck, Germany 
49.   Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA 
50.   Cardiovascular Epidemiology and Genetics, IMIM. Dr Aiguader 88, Barcelona, 08003, Spain 
51.   Institute of Genetics and Biophysics A. Buzzati-Traverso, CNR, via P. Castellino 111, 80131 
Napoli, Italy 
52.   Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 7 George 
Square, Edinburgh EH8 9JZ, UK 
53.   Department of Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre, 
Beaumont Hospital, Dublin, Ireland 
54.   University College Dublin, UCD Conway Institute, Centre for Proteome Research, UCD, Belfield, 
Dublin, Ireland 
55.   Department of Immunology, Genetics and Pathology, Uppsala Universitet, Science for Life 
Laboratory, Husargatan 3, Uppsala, SE-75108, Sweden 
56.   Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann 
Arbor, MI 48109, USA 
57.   Department of Cardiovascular Sciences, University of Leicester, Leicester LE3 9QP, UK 
58.   NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester LE3 9QP, 
UK 
59.   MRC Human Genetics Unit, IGMM, University of Edinburgh, Western General Hospital, 
Edinburgh, EH4 2XU Scotland, UK 
5 
 
60.   Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, 
London W2 1PG, United Kingdom 
61.   Department of Cardiology, Ealing Hospital NHS Trust, Uxbridge Road, Southall, Middlesex UB1 
3EU, UK 
62.   MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of 
Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK 
63.   Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental 
Medicine and MRC Institute of Genetics and Molecular Medicine, Western General Hospital, Crewe 
Road, Edinburgh EH4 2XU, UK 
64.   Department of Biology, Faculty of Medicine, University of Split, Croatia 
65.   The Charles Bronfman Institute for Personalized Medicine, Icachn School of Medicine at Mount 
Sinai, New York, NY 10029, USA 
66.   Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 
45110, Greece 
67.   Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, 
Dundee, DD1 9SY, Scotland, UK 
68.   Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, 22060, 
Pakistan 
69.   Department of Internal Medicine, Division of Nephrology, University of Groningen, University 
Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands 
70.   Department of Twin Research and Genetic Epidemiology, King’s College London, Lambeth 
Palace Rd, London, SE1 7EH, UK 
71.   National Institute for Health Research Biomedical Research Centre, London SE1 9RT, UK 
72.   Department of Human Genetics, Wellcome Trust Sanger Institute, CB10 1HH, United Kingdom 
73.   Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics 
and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK 
74.   Generation Scotland, Centre for Genomic and Experimental Medicine, University of Edinburgh, 
Edinburgh, EH4 2XU, UK 
75.   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The 
Netherlands 
76.   INSERM U 1219, Bordeaux Population Health center, Bordeaux, France 
77.   Bordeaux University, Bordeaux, France 
78.   Hunter Medical Research Institute, New Lambton, NSW 2305, Australia 
79.   Center for Statistical Genetics, Dept. of Biostatistics, SPH II, 1420 Washington Heights, Ann 
Arbor, MI 48109-2029, USA 
80.   Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, 
Iran 
81.   Busselton Population Medical Research Institute, Western Australia 
82.   PathWest Laboratory Medicine of Western Australia, NEDLANDS, Western Australia 
83.   School of Pathology and Laboratory Medicine, The University of Western Australia, NEDLANDS, 
Western Australia 
84.   For a complete list of contributing authors, please see Supporting Information. 
85.   Imperial College Healthcare NHS Trust, London, UK 
86.   Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, 
NIH, Bethesda, MD 20892, USA 
6 
 
87.   University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK 
88.   Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK 
89.   Department of Pathology, Amsterdam Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, 
The Netherlands 
90.   Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh, EH8 9JZ, UK 
91.   Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, 2300RC, The 
Netherlands 
92.   Center for Information Technology, NIH, USA 
93.   Department of Internal Medicine B, University Medicine Greifswald, Greifswald, 17475, 
Germany 
94.   Department of Numerical Analysis and Computer Science, Stockholm University, 
Lindstedtsvägen 3, Stockholm, 100 44, Sweden 
95.   Department of Public Health and Caring Sciences, Geriatrics, Uppsala 752 37, Sweden 
96.   Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fuer Gesundheit und Umwelt 
(GmbH), Ingolstaedter Landstr. 1, 85764 Neuherberg, München, Germany 
97.   Department of Psychology, School of Life Sciences, Heriot-Watt University, Edinburgh, EH14 
4AS, UK 
98.   Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, 
National Institute on Aging, USA 
99.   Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, 
USA 
100.   School of Population and Global Health, The University of Western Australia, NEDLANDS, 
Western Australia 
101.   Center For Life-course Health Research, P.O. Box 5000, FI-90014 University of Oulu, Finland 
102.   Biocenter Oulu, P.O. Box 5000, Aapistie 5A, FI-90014 University of Oulu, Finland 
103.   Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, P.O. Box 20, FI-90220 Oulu,  
90029 OYS, Finland 
104.   MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics,  
School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK 
105.   National Heart, Lung and Blood Institute, Cardiovascular Epidemiology and Human Genomics 
Branch, Bethesda, MD 20814, USA 
106.   Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland 
107.   Department of Clinical Physiology, Faculty of Medicine and Life Sciences, University of 
Tampere, Tampere 33014, Finland 
108.   Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA 
109.   Center for Human Genetics, Massachusetts General Hospital, 185 Cambridge Street, Boston, 
MA 02114, USA 
110.   Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, 
MA 02142, USA 
111.   Department of Public Health and Primary Care, Institute of Public Health, University of 
Cambridge, Cambridge CB2 2SR, UK 
112.   Department of Public Health, Faculty of Medicine, University of Split, Croatia 
113.   See complete listing of contributors in the Supporting Information. 
114.   Cardiology, Department of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 
4, 1211 Geneva 14, Switzerland 
7 
 
115.   Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala 
751 85, Sweden 
116.   Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK 
117.   Department of Psychiatry, EMGO Institute for Health and Care Research, VU University 
Medical Center, A.J. Ernststraat 1187, 1081 HL Amsterdam, The Netherlands 
118.   School of Molecular, Genetic and Population Health Sciences, University of Edinburgh, Medical 
School,Teviot Place, Edinburgh, EH8 9AG, Scotland, UK 
119.   Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public 
Health, University of Texas Health Science Center at Houston, 1200 Pressler St., Suite 453E, Houston, 
TX 77030, USA 
120.   Interdisciplinary Center Psychopathology and Emotion Regulation (IPCE), University of 
Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, 
The Netherlands 
121.   British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular 
and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
Glasgow G12 8TA, UK 
122.   Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland 
123.   Department of Pathology and Molecular Medicine, McMaster University, 1280 Main St W, 
Hamilton, L8S 4L8, Canada 
124.   School of Public Health, Imperial College London, W2 1PG, UK 
125.   Department of Neurology, General Central Hospital, Bolzano, Italy 
126.   Department of Neurology, University of Lübeck, Lübeck, Germany 
127.   Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku 
20521, Finland 
128.   Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, 
Turku 20014, Finland 
129.   Department of Cardiology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou 
350001, China 
130.   Department of Biostatistics University of Washington, Seattle, WA 98101, USA 
131.   Harvard Medical School, Boston MA, USA 
132.   Institute for Maternal and Child Health IRCCS Burlo Garofolo, Via dell'Istria 65, Trieste, 34200, 
Italy 
133.   The Institute for Translational Genomics and Population Sciences, Departments of Pediatrics 
and Medicine, LABioMed at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 
90502, USA 
134.   Institute of Molecular Biology and Biochemistry, Centre for Molecular Medicine, Medical 
University of Graz, Harrachgasse 21, 8010 Graz, Austria 
135.   INSERM U1078, Etablissement Français du Sang, 46 rue Félix Le Dantec, CS 51819, Brest Cedex 
2 29218, France 
136.   Faculty of Health, University of Newcastle, Callaghan NSW 2308, Australia 
137.   John Hunter Hospital, New Lambton NSW 2305, Australia 
138.   School of Medicine, Conway Institute, University College Dublin, Ireland 
139.   The New York Academy of Medicine. 1216 5th Ave, New York, NY 10029, USA 
140.   IRCCS Neuromed, Pozzilli, Isernia, Italy 
141.   Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland 
8 
 
142.   Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, 
United Kingdom 
143.   Department of Genetics, University of Groningen, University Medical Center Groningen, PO 
Box 30001, 9700 RB Groningen, The Netherlands 
144.   Institute for Translational Genomics and Population Sciences. Los Angeles BioMedical 
Research Institute at Harbor-UCLA Medical Center, Torrance, CA, 90502, USA 
145.   Division of Genetic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, 
Torrance, CA, 90502, USA 
146.   International Centre for Circulatory Health, Imperial College London, W2 1PG, UK 
147.   Department of Public Health, Bordeaux University Hospital, Bordeaux, France 
148.   Department of Internal Medicine, Erasmus MC, Rotterdam, 3000CA, The Netherlands 
149.   Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, 
Greifswald, 17475, Germany 
150.   Department of Internal Medicine, Lausanne Universiyt Hospital, CHUV, 1011 Lausanne, 
Switzerland 
151.   Population Health Research Institute, McMaster University, Hamilton Ontario, Canada 
152.   National Heart and Lung Institute, Imperial College London, W2 1PG, UK 
153.   Department of Neurology, Bordeaux University Hospital, Bordeaux, France 
154.   Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The 
Netherlands 
155.   Department of Cardiology, University of Groningen, University Medical Center Groningen, PO 
Box 30001, 9700 RB Groningen, The Netherlands 
156.   The Charles Bronfman Institute for Personalized Medicine, The Icahn School of Medicine at 
Mount Sinai, New York, NY 10029, USA 
157.   Mindich Child health Development Institute, The Icahn School of Medicine at Mount Sinai, 
New York, NY 10029, USA 
158.   Alzheimer Scotland Dementia Research Centre, University of Edinburgh, 7 George Square, 
Edinburgh, EH8 9JZ, UK 
159.   Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, 
University of Edinburgh, Edinburgh EH4 2XU, UK 
160.   National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, 
Du Cane Road, London W12 0NN, UK 
161.   Diabetes Prevention Unit, National Institute for Health and Welfare, 00271 Helsinki, Finland 
162.   South Ostrobothnia Central Hospital, 60220 Seinäjoki, Finland 
163.   Red RECAVA Grupo RD06/0014/0015, Hospital Universitario La Paz, 28046 Madrid, Spain 
164.   Centre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria 
165.   Institute of Cardiovascular Sciences, The University of Manchester, Manchester, UK 
166.   Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila Str. 19, 50412 
Tartu, Estonia 
167.   Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, 27106, 
USA 
168.   University of Tartu, Tartu, Estonia 
169.   Department of Neurology, Medical University Graz, Auenbruggerplatz 22, 8036 Graz, Austria 
170.   Department of Epidemiology University of Washington, Seattle, WA 98101, USA 
171.   Department of Health Services, University of Washington, Seattle, WA 98101, USA 
9 
 
172.   Group Health Research Institute, Group Health, Seattle, WA, 98101, USA 
173.   Institute of Physiology, University Medicine Greifswald, Karlsburg, 17495, Germany 
174.   Department of Pulmonary Physiology and Sleep, Sir Charles Gairdner Hospital, Hospital 
Avenue, Nedlands 6009,H57, Western Australia 
175.   School of Medicine and Pharmacology, University of Western Australia, Australia 
176.   Population Health Research Institute, St George's, University of London, London SW17 0RE, UK 
177.   Department of Medicine, Columbia University Medical Center, 622 West 168th Street, PH 9, 
East, 107, New York, NY 10032, USA 
178.   Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, 
Uppsala University, Uppsala 752 37, Sweden 
179.   Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of 
Medicine, Stanford, CA 94305, USA 
180.   Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA 
181.   Data Science Institute and Lancaster Medical School, Lancaster University, LA1 4YG, UK 
182.   Department of Biostatistics, University of Liverpool, Block F, Waterhouse Building, 1-5 
Brownlow Street, Liverpool L69 3GL, UK 
183.   The population Science Branch, Division of Intramural Research, National Heart Lung and 
Blood Institute national Institute of Health, Bethesda MD 20892, USA 
 
Corresponding authors: Louise V. Wain (louisewain@le.ac.uk) and Georg B. Ehret (georg@jhmi.edu) 
  
10 
 
ABSTRACT 
Elevated blood pressure is a major risk factor for cardiovascular disease and has a substantial genetic 
contribution. Genetic variation influencing blood pressure has the potential to identify new 
pharmacological targets for the treatment of hypertension. To discover additional novel blood 
pressure loci, we used 1000 Genomes Project-based imputation in 150,134 European ancestry 
individuals and sought significant evidence for independent replication in a further 228,245 
individuals. We report 6 new signals of association in or near HSPB7, TNXB, LRP12, LOC283335, SEPT9 
and AKT2, and provide new replication evidence for a further 2 signals in EBF2 and NFKBIA. Combining 
large whole-blood gene expression resources totaling 12,607 individuals, we investigated all novel 
and previously reported signals and identified 48 genes with evidence for involvement in BP 
regulation that are significant in multiple resources.  Three novel kidney-specific signals were also 
detected. These robustly implicated genes may provide new leads for therapeutic innovation. 
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INTRODUCTION 
Genetic support for a drug target increases the likelihood of success in drug development 1 and there 
is clear unmet need for novel therapeutic strategies to treat individuals with hypertension 2. A 
number of large studies have described blood pressure (BP) variant identification by genome-wide 
and targeted association approaches 3-19. Clinically the most predictive BP traits for cardiovascular 
risk are systolic blood pressure (SBP) and diastolic blood pressure (DBP), reflecting roughly the peak 
and trough of the BP curve, and pulse pressure (PP), the difference between SBP and DBP 20 
reflecting arterial stiffness.  Using these three traits, we undertook a meta-analysis of 150,134 
individuals from  54 genome-wide association studies of European ancestry with imputation based 
on the 1000 Genomes Project Phase 1. To minimize reporting of false positive associations, we 
sought stringent evidence for significant independent replication in a further 228,245 individuals. 
We further followed up novel and previously reported association signals in multiple large gene 
expression databases and the largest kidney tissue gene expression resource currently available. 
Finally, we searched for enrichment of associated genes in biological pathways and gene sets and 
identified whether any of the genes were known drug targets or had tool molecules. 
MATERIALS AND METHODS 
Studies Stage 1 
Results from 54 independent European-ancestry studies, totaling 150,134 individuals, were included 
in the Stage 1 meta-analysis: AGES (n=3215), ARIC (n=9402), ASPS (n=828), B58C (n=6458), BHS 
(n=4492), CHS (n=3254), Cilento study (n=999), COLAUS  (n=5404), COROGENE-CTRL (n=1878), 
CROATIA-Vis (n=945), CROATIA-Split (n=494), CROATIA-Korcula (n=867), EGCUT (n=6395), EGCUT2 
(n=1844), EPIC (n=2100), ERF (n=2617), Fenland (n=1357), FHS (n=8096), FINRISK-ctrl (n=861), 
FINRISK CASE (n=839), FUSION (n=1045), GRAPHIC (n=1010), H2000-CTRL (n=1078), HealthABC  
(n=1661), HTO (n=1000), INGI-CARL (n=456), INGI-FVG (n=746), INGI-VB (n=1775), IPM (n=300), 
KORAS3 (n=1590), KORAS4 (n=3748), LBC1921 (n=376), LBC1936 (n=800), LOLIPOP-EW610 (n=927), 
MESA (n=2678), MICROS (n=1148), MIGEN (n=1214), NESDA (n=2336), NSPHS (n=1005), NTR 
(n=1490), PHASE (n=4535), PIVUS (n=945), PROCARDIS (n=1652), SHIP (n=4068), ULSAM (n=1114), 
WGHS (n=23049), YFS (n=1987), ORCADES (n=1908), RS1 (n=5645), RS2 (n=2152), RS3 (n=3018), 
TRAILS (n=1262), TRAILS-CC (n=282) and TWINGENE (n=9789). Full study names and general study 
information is given in Supplementary Table 1. 
 
Study-level genotyping and association testing 
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Three quantitative BP traits were analyzed: SBP, DBP, and PP (difference between SBP and DBP). 
Within each study, individuals known to be taking anti-hypertensive medication had 15 mmHg 
added to their raw SBP value and 10 mmHg added to their raw DBP values 21. A summary of BP 
phenotypes in each study is given in Supplementary Table 2. Association testing was undertaken 
according to a central analysis plan that specified the use of sex, age, age2, and body mass index 
(BMI) as covariates and optional inclusion of additional covariates to account for population 
stratification (Supplementary Table 3). Trait residuals were calculated for each trait using a normal 
linear regression of the medication-adjusted trait values (mmHg) onto all covariates. The genotyping 
array, pre-imputation quality control filters, imputation software and association testing software 
used by each study are listed in Supplementary Table 4. All studies imputed to the 1000 Genomes 
Project Phase 1 integrated release version 3 [March 2012] all ancestry reference panel 22. Imputed 
genotype dosages were used to take into account uncertainty in the imputation. Association testing 
was carried out using linear regression of the trait residuals onto genotype dosages under an 
additive genetic model. Methods to account for relatedness within a study were used where 
appropriate (Supplementary Table 3). Results for all variants (SNPs and INDELs) were then returned 
to the central analysis group for further quality control checks and meta-analysis. 
Stage 1 meta-analysis 
Central quality control checks were undertaken across all results sets. This included checks to ensure 
allele frequency consistency (across studies and with reference populations), checks of effect size 
and standard error distributions (i.e. to highlight phenotype issues) and generation of quantile-
quantile (QQ) plots and genomic inflation factor lambdas to check for over- or under-inflation of test 
statistics. Genomic control was applied (if lambda>1) at study-level. Variants with imputation quality 
<0.3 were excluded prior to meta-analysis. Inverse variance weighted meta-analysis was undertaken. 
After meta-analysis, variants with a weighted minor allele frequency of less than 1 % or N effective 
(product of study sample size and imputation quality summed across contributing studies) <60% 
were then excluded and meta-analysis genomic control lambda calculated and used to adjust the 
meta-analysis results.  
Selection of regions for follow-up 
For each trait, regions of association were selected by ranking variants by P value, recording the 
variant with the lowest P value as a sentinel variant and then excluding all variants +/-500kb from 
the sentinel and re-ranking the remaining variants. This was undertaken iteratively until all sentinel 
variants representing 1Mb regions containing associations with P <10-6 had been identified. To 
identify additional signals represented by secondary sentinel variants within 500kb of each of the 
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sentinel variants, GCTA 23 was used to run conditional analyses (conditioned on the first sentinel 
variant) on each of the 1Mb regions using GWAS summary statistics and LD information from ARIC. 
This was done both for putatively novel regions and for regions that had previously been reported. A 
chi-squared test of heterogeneity of effect sizes across the 54 studies was run for each sentinel 
variant and those with P <0.05 for heterogeneity were excluded from further follow-up. Variants 
with P <10-6 after conditioning on the sentinel SNP (novel or known) in the region and for which any 
attenuation of the –log10 P value was less than 1.5 fold, were also taken forward for replication. 
Studies stage 2 
Data from 14 independent studies, totaling 87,360 individuals, and the first release of UK Biobank, 
totaling 140,886 individuals, were combined to replicate the findings from stage 1 (i.e. totaling 
228,245 individuals). Stage 2 study details, including full study names, are given in Supplementary 
Table 6 and included 3C-Dijon (n=4061), Airwave (n=14023), ASCOT-SC (n=2462), ASCOT-UK 
(n=3803), BRIGHT (n=1791), GAPP (n=1685), GoDARTs (n=7413), GS:SFHS (n=9749), HCS (n=2112), 
JUPITER (n=8718), LifeLines (n=13376), NEO (n=5731), TwinsUK (n=4973), UK Biobank-CMC 
(n=140,886) and UKHLS (n=7462). Analysis was undertaken using the same methods as described for 
Stage 1 studies. UK Biobank-CMC utilized a newer imputation reference panel than the other studies 
and where a requested variant was not available, a proxy was used (next most significant P value 
with linkage disequilibrium r2> 0.6 with original top variant).  Results from all stage 2 studies were 
meta-analyzed using inverse-variance weighted meta-analysis. Two of the variants, rs1048238 and 
chr1:243458005:I, were not available in the largest study in Stage 2 (UK Biobank-CMC) and so proxy 
variants were selected (based on P value and LD). 
Stage 1 + Stage 2 meta-analysis 
Following meta-analysis of stage 1 and stage 2 results, signals with a P > 5x10-8 were excluded. Of 
the signals with a final P <5x10-8, support for independent replication within the stage 2 studies only 
was sought. Any signals which had P < 5x10-8 and evidence for independent replication in stage 2 
alone, indicated by P < 8.2x10-4 (Bonferroni correction for 61 tests) were reported as novel signals of 
association with BP. Any signals which were subsequently reported by other BP GWAS that were 
accepted for publication during the time this analysis was ongoing, or signals for which 
independence from another known signal could not be established, were removed from our list of 
novel signals at this stage (Supplementary Table 5). 
Genotype and gene expression 
We searched for signals of association of genotype with gene expression for the 22 signals (including 
8 novel) signals described in this study (Supplementary Table 7) and all signals reported prior to our 
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study (Supplementary Table 10) 3-17, 24 in 3 whole-blood data sets, 1 kidney data set and the GTEx 
multiple tissue data resource, which included whole-blood 25. We selected cis signals of association 
which were significant after controlling for 5% False Discovery Rate (FDR). The 3 whole-blood eQTL 
data sets were the NHLBI Systems Approach to Biomarker Research in Cardiovascular Disease 
initiative whole-blood eQTL resource (SABRe) (microarray, n=5257), NESDA-NTR (microarray, 
n=4896), BIOS (RNAseq, n=2116). The whole-blood data from GTEx was based on data from 338 
samples. The kidney data set comprised 236 donor-kidney samples from 134 donors 26. Full details of 
each data set can be found in the Supporting Information. The source transcriptomic renal data as 
described26 have been deposited in the GeneExpression Omnibus (NCBI) and are accessible online 
through GEO Series accession number GSE43974. 
LD lookup 
The 1000 Genomes Project phase 3 release of variant calls was used (Feb. 20th, 2015), using 503 
subjects of European ancestry22. r2 between the sentinel SNPs and all other bi-allelic SNPs within the 
corresponding 2 Mb area was calculated using the Tabix and PLINK software package (v1.07) 27, 28. 
Annotation was performed using the ANNOVAR software package29. 
Gene-based pathway analysis 
All genes identified in 3 or 4 of the whole-blood eQTL resources above (Table 2), and genes 
containing a non-synonymous variant with r2>0.5 with the sentinel variant (Supplementary Table 
13), were tested for enrichment of biological pathways and gene ontology terms using 
ConsensusPathDB 30 using a FDR<5% cut-off.  Enriched pathways and GO terms containing genes 
only implicated by a single BP-associated variant were not reported. 
Network analysis 
To construct a functional association network, we combined two prioritized candidate gene sets into 
a single query gene set as (i) genes mapping to the non-synonymous SNPs (nsSNPs) in high LD 
(r2>0.5) with the corresponding sentinel BP associated SNP, and (ii) genes with eQTL evidence from 3 
or 4 of the blood eQTL resources. Three sentinel SNPs (rs185819, rs926552 and rs805303) mapping 
to the HLA region on chromosome 6 were excluded from downstream analyses. The single query 
gene set was then used as input for the functional network analysis31. We used the Cytoscape 32 
software platform extended by the GeneMANIA33 plugin (Data Version: 8/12/2014)34. All the genes 
in the composite network, either from the query or the resulting gene sets, were then used for 
functional enrichment analysis against Gene Ontology terms (GO terms) 35 to identify the most 
relevant GO terms using the same plugin 34. 
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DNase1 Hypersensitivity overlap enrichment across tissue and cell-types 
The Functional element Overlap analysis of the Results of Genome Wide Association Study (GWAS) 
Experiments (Forge tool v1.1)36 was used to test for enrichment of overlap of BP SNPs in tissues and 
cell lines from the Roadmap and ENCODE projects. All 164 SNPs were entered and 143 were 
included in the analysis. SNPs from 9 commonly used GWAS arrays were used to select background 
sets of SNPs for comparison and 10,000 background repetitions were run. A Z-score threshold of 
>=3.39 (estimated false positive rate of 0.5%) was used to declare significance. 
Drug-gene interactions 
Genes used for pathway and gene ontology enrichment analyses were further investigated for 
potential druggable or drugged targets using the drug gene interaction database (DGIdb). Known 
drug-gene interactions were interrogated across 15 source databases in DGIdb and include all types 
of interactions. The analysis performed for druggability prediction included all 9 databases 
exclusively inspecting expert curated data only. We also evaluate genes for known tool compounds 
using Chembl (www.ebi.ac.uk/chembl/; version 22.1). 
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RESULTS 
The stage 1 discovery meta-analysis included 150,134 individuals  (Online Methods; Supplementary 
Tables 1-4, Supplementary Figures 1 and 2) and 7,994,604 variants with minor allele frequency 
(MAF) >1% and an effective sample size of at least 60% of the total (Online Methods).  We identified 
61 signals in the discovery analysis that were candidates for novel BP signals (P < 10-6 for any trait; 
Supplementary Table 5). To ensure robustness of signals, we examined BP associations in an 
additional 228,245 individuals from 15 independent studies for replication, including 140,886 
individuals from UK Biobank 19 (Supplementary Table 6 and Online Methods). We used the most 
significant (“sentinel”) SNP and trait for each locus in replication (61 tests).  Twenty-two putatively 
novel association signals were initially confirmed showing significant evidence of replication in the 
independent stage-2 studies (P < 8.2x10-4, Bonferroni correction for 61 tests) and genome-wide 
significance (P < 5x10-8) in a meta-analysis across all 378,376 individuals (Online methods, Table 1, 
Supplementary Table 7). Of these, 14 were subsequently published in two other studies 18, 19 which 
presented genome-wide significant associations with evidence of replication. A further two were 
highlighted as putative novel signals in one of those studies 18 but had not been confirmed by 
replication. In our study, we report the 6 remaining novel signals, and the 2 previously unconfirmed 
signals (in EBF2 and in NFKBIA), as novel signals. The 8 novel signals included 7 signals at 7 
independent loci (Supplementary Figure 3) and one novel independent signal near a previously 
reported hit near TNXB (Online Methods, Supplementary Table 8, Supplementary Figure 4). The 
novel signals show both significant evidence of replication in the independent stage-2 studies (P < 
8.2x10-4, Bonferroni correction for 61 tests) and genome-wide significance (P < 5x10-8) in a meta-
analysis across all 378,376 individuals. The sentinel variants at all 8 signals were common (MAF>5%) 
and the novel secondary signal at TNXB was in high linkage-disequilibrium (r2 > 0.8) with a non-
synonymous SNP. With the exception of rs9710247, which was only significant for association with 
DBP, all signals were significantly associated (P<0.006, Bonferroni corrected for 8 tests) with all 3 
traits (Table 1 and Supplementary Table 9). 
We next sought to identify which genes might have expression levels that were associated with 
genotypes of the BP-associated variants reported in this study and others. Strong evidence of an 
association with expression of a specific gene may provide clues as to which gene(s) might be 
functionally relevant to that signal.  We took the 139 BP association signals reported prior to these 
studies 18, 19, and 22 novel signals of association identified and confirmed in this study and two 
contemporaneous studies 3-19, 24 (Supplementary Table 10), and searched for evidence of association 
with gene expression in whole-blood (four studies, total n=12,607; Online Methods) and in kidney 
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tissue (n=134, the largest kidney eQTL resource currently available).  Although of unclear direct 
relevance to BP, whole-blood was studied due to the availability of large data sets enabling a 
powerful assessment of expression patterns that are likely present across multiple cell and tissue 
types. Similarly, circulating blood cells have been used for ion transport experiments in the past and 
altered ion transport levels in erythrocytes were linked to hypertension.37  Kidney was chosen 
because of the many renal pathways that regulate BP and outstanding questions about the 
relevance of kidney pathways to the genetic component of BP regulation in the general population 3, 
15. Expression quantitative trait loci (eQTL) signals were filtered by false discovery rate (FDR<5%) and 
we examined cis (within 1Mb) associations only (Online methods and Supporting Information). 
The four blood eQTL data sets were NESDA-NTR 38, 39, SABRe 15, the BIOS resource 40 and GTEx25 
(Online Methods and Supporting Information). The BIOS resource (n=2,116) has not previously 
been utilized in the analysis of BP associations, findings from NESDA-NTR and SABRe have been 
reported for a subset of the previously published signals 16, 17. For a total of 369 genes, gene-
expression was associated with the BP SNP in one or more of the 4 blood datasets at experiment-
wide significance (Supplementary Table 11). This included 14 genes for 6 of the 8 novel signals. For 
110 genes, we found eQTL evidence in 2 out of 4 datasets (Figure 1), including 4 genes for 2 of the 
novel signals; EIF4B and TNS2 for rs73099903 and MAP3K10 and PLD3 for rs9710247.  SNP 
rs73099903 was in strong linkage disequilibrium (LD r2>0.9) with the SNP most strongly associated 
with TNS2 expression in the BIOS resource. TNS2 encodes a tensin focal adhesion molecule and may 
have a role in renal function 41. 
For 48 genes, we found evidence in 3 out of the 4 resources (Table 2), suggesting robustness of the 
SNP-gene expression correlation signal and highlighting those genes as potential candidates in 
genetic BP regulation. Of the 48 genes, 28 have not previously been described in eQTL analyses using 
BP associated SNPs and all were correlated with previously reported BP association signals. 
In the kidney dataset (TransplantLines) 26, there was association of gene expression and genotype for 
nine SNPs and 13 genes (Table 2, Figure 1 and Supplementary Table 12). Nine of the SNP-gene 
expression associations were also observed in the whole-blood eQTL datasets, suggesting that those 
signals may not be unique to the kidney. We report three signals that were unique to the kidney and 
not previously reported (C4orf34, HIP2 and ASIC1) and confirm a previously reported kidney eQTL 
signal for an anti-sense RNA for PSMD5 15. The same SNP was also an eQTL for PSMD5 itself in both 
blood and kidney. ASIC1 encodes the Acid Sensing Ion Channel Subunit 1 which may interact (and be 
co-expressed) with ENaC subunits which mediate trans-epithelial Na transport in the distal nephron 
of the kidney 42. The comparatively small number of signals using kidney tissue (Table 2 and Figure 1) 
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compared to whole-blood could be due to the small sample size. Complete GTEx results are in 
Supplementary Table 13. 
For genes implicated by eQTL information from whole-blood, we tested for enrichment of biological 
pathways and gene ontologies (Online Methods). We noted enrichment of the 48 genes implicated 
by 3 or 4 blood eQTL resources, Table 2, and a further 53 genes containing a non-synonymous 
variant with r2 > 0.5 with the top SNP (Supplementary Table 14), in pathways and ontology terms 
related to actin and striated muscle (Supplementary Tables 15 and 16, Online Methods). Network 
analysis using the same genes highlighted further GO terms relating to muscle function, particularly 
cardiac muscle (Online Methods, Supplementary Table 17). We tested the overlap of 161 non-HLA 
BP associated variants with DNase Hypersensitivity sites identified in the Roadmap and ENCODE cell 
lines (Online Methods) and identified an overall enrichment in multiple cell and tissue types 
including heart, kidney and smooth muscle (Supplementary Figure 5). 
We next investigated these genes for potential suitability as drug targets (druggability), known tool 
compounds and clinically approved drugs using the drug gene interaction database (DGIdb) 43 
(Supplementary Table 18). Twelve genes had known drugs, including four genes with known 
antihypertensive drugs. We noted that drugs modulating all but one of the 12 drugged targets had a 
reported influence on blood pressure, either as a primary antihypertensive indication or as a 
reported side effect of raised blood pressure. Twenty additional genes were predicted druggable, 
among these 7 genes have known small molecule tool modulators, based on a query of the Chembl 
database (www.ebi.ac.uk/chembldb/; version 22.1).  
DISCUSSION 
Enhanced discovery of BP loci increases the potential targets for therapeutic advances. After major 
advances in the number of BP loci known over the last years and months, we report 8 novel signals 
that implicate 5 regions of the genome not previously connected to blood pressure regulation.  
Six of the 8 novel signals we report had not previously been reported. Two signals (in EBF2 and 
NFKBIA) have been suggested previously but without evidence for replication 18. For these two 
signals we present, for the first time, stringent evidence of replication, confirming their relevance to 
blood pressure genetics. 
The path from signal to genes is the essential next step towards realizing the therapeutic potential of 
a genetic locus and understanding the mechanisms of BP regulation. We have used several large 
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eQTL resources as a first step to realize this objective. As expected, we observed that even across 
eQTL studies of the same tissue, there is limited overlap in experiment-wide significant signals 
suggesting either biologic variability (differences in the characteristics of the samples or in the 
methods for extraction and processing of mRNA in each of the studies), technology-specific 
differences in coverage of genes (use RNAseq data for the BIOS blood dataset and microarray-based 
expression levels for the kidney and other blood datasets), or the possibility of false positive results 
despite stringent within-experiment significance thresholds. We were unable to distinguish these 
scenarios using the data available to us but by selecting genes that were significant in at least three 
resources, and therefore robust to these differences, we identified 48 genes as candidates for 
further study. These results are limited by the availability of large eQTL resources for whole-blood 
only, which precludes well-powered comparisons across tissue types, particularly as the origin of 
blood pressure control is unlikely to be located in the blood. Enrichment and pathway analyses using 
these genes, and genes containing a correlated functional variant, highlight the potential relevance 
of muscular tissue and pathways, compatible with a vascular and cardiac origin of BP genetics, 
extending previous evidence 15.  We identify a number of drugged targets in the pathways identified, 
including four existing hypertension targets. Other drugs identified are not suitable candidates for 
repositioning to hypertension, as most were reported in adverse events to raise blood pressure, 
however the targets would be valid for investigation using a reverse mechanism, e.g. agonism in 
place of inhibition. We also identified seven genes with small molecule tool modulators (mainly 
inhibitory or binding). These molecules and targets might be suitable candidates for further 
investigation to build a target validation case to support clinical investigation in hypertension. 
Amongst the genes implicated in our eQTL analyses were several for which there is already some 
evidence that they are relevant to blood pressure regulation. The intronic SNP rs10926988 was 
independently associated with expression of SDCCAG8 in all four whole-blood resources. Rare 
mutations in SDCCAG8 cause Bardet-Biedl syndrome, which features hypertension. Expression levels 
of MYBPC3 were correlated with rs710364815 in the 3 largest blood eQTL resources (i.e. SABRe, 
NESDA-NTR and BIOS). MYBPC3 encodes the cardiac isoform of myosin-binding protein C, which is 
expressed in heart muscle and mutations in MYBPC3 are known to cause familial hypertrophic 
cardiomyopathy.44 
This study has several limitations: Given the nature of statistical power for genome-wide association 
analyses, the sample size is limited, even though this is one of the largest efforts in BP GWAS 
undertaken so far. The study would clearly have benefited from the availability of larger eQTL 
resources on multiple tissues in sample sizes even larger than those available today. Our analyses 
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were limited to cis-signals and future analyses, with larger sample sizes, might also consider trans-
signals. 
In summary, our study reports novel BP association signals and reports new candidate BP genes, 
contributing to the transition from variants to genes to explain BP variation. 
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NOVELTY AND SIGNIFICANCE 
What is New: The root origin of hypertension and hence blood pressure variability in the population 
remains unclear. This study adds data to explain the genetic basis of blood pressure variability and 
identifies genes likely active in blood pressure regulating pathways. 
What Is Relevant: The results are of relevance for scientists, clinicians, and pharmacologists 
interested in hypertension. The BP loci and the BP genes identified constitute new leads for the 
understanding of BP pathogenesis and possibly therapeutic innovation. 
Summary: Using 1000 Genomes Project-based imputation in 150,134 European ancestry and 
independent replication in a further 228,245 individuals we contribute 8 replicated blood pressure 
loci to the collection of loci currently known. Using these and previous data, 48 BP genes are 
identified for priority follow-up. 
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FIGURE LEGENDS 
Figure 1: Overlap of eQTL evidence from four whole-blood and one kidney resource 
The figure indicates overlap of evidence for eQTLs from four whole-blood studies (SABRe, NESDA-
NTR, BIOS, and GTEx) and from one kidney resource (TransplantLines). Every colored line indicates 
that this gene was analysis-wide significant in a given resource (see Online Methods). Only genes 
identified by at least two resources are shown.  The genes are sorted by genomic position on the y-
axis. 
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FIGURES 
Figure 1 
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Table 1.  Novel genome-wide significant signals of association 
Results from stage 1 and stage 2, and the meta-analysis of stage 1 and stage 2, for all novel genome-wide significant signals of association. P values of 
association for all 3 traits from a meta-analysis of stages 1 and 2 are also presented. Genome-wide significant P values (P<5x10-8) are in bold. Abbreviations: 
CAF: coded allele frequency se: standard error, Neff: effective sample size. #Novel signal at previously reported locus. 1For intragenic variants the nearest 
genes are listed, all other variants are intronic unless indicated otherwise; ns= non-synonymous, s=synonymous, UTR= Untranslated Region. Results from 
proxy SNPs are indicated by (proxy); rs848309 was a proxy SNP for rs1048238 and rs10926988 was a proxy SNP for chr1:243458005:I. 
  Results for most significant trait Stage 1 + stage 2 meta-analysis P 
values for all traits   Stage 1 Stage 2 Stage 1+ stage 2 
Variant ID (noncoded/coded 
allele)  
chr:position, Nearest 
gene(s)(type1) 
CAF Beta (se) P value Neff Beta  
(se) 
P value Neff Beta (se) P value Neff SBP DBP PP 
SBP 
rs1048238 (C/T) 
1:16341649, HSPB7 (3’UTR) 
0.571 0.366 
(0.074) 
8.09E-07 140299 NA NA NA NA NA NA NA NA NA 
rs848309(proxy) (T/C) 
1:16308447 
0.567 0.347 
(0.072) 
1.70E-06 146755 0.347 
(0.071) 
9.10E-07 140462 0.347 
(0.051) 
7.07E-12 287217 7.07E-12 1.07E-10 5.48E-06 
#rs185819 (T/C) 
6:32,050,067, TNXB (ns) 
0.513 0.534 
(0.073) 
1.93E-13 142397 0.277 
(0.053) 
1.49E-07 221748 0.365 
(0.043) 
1.04E-17 364144 1.04E-17 2.24E-11 8.50E-15 
rs6557876 (C/T) 
8:25,900,675, EBF2 
0.252 -0.411 
(0.084) 
8.50E-07 143653 -0.350 
(0.060) 
5.66E-09 225803 -0.371 
(0.049) 
2.85E-14 369457 2.85E-14 2.50E-10 1.51E-08 
rs35783704 (G/A) 
8:105,966,258, LRP12/ZFPM2 
0.109 -0.609 
(0.121) 
4.96E-07 133924 -0.310 
(0.089) 
4.78E-04 215528 -0.414 
(0.072) 
7.08E-09 349452 7.08E-09 1.60E-06 2.92E-07 
rs73099903 (C/T) 
12:53,440,779, LOC283335 
0.074 0.768 
(0.143) 
8.05E-08 136064 0.396 
(0.098) 
5.32E-05 207253 0.515 
(0.081) 
1.95E-10 343318 1.95E-10 4.53E-06 5.46E-08 
rs8904 (G/A) 
14:35,871,217, NFKBIA (3’ UTR) 
0.375 0.377 
(0.076) 
6.76E-07 140424 0.278 
(0.054) 
2.31E-07 224771 0.311 
(0.044) 
1.31E-12 365195 1.31E-12 1.13E-04 3.44E-12 
rs57927100 (C/G) 
17:75,317,300, SEPT9 
0.258 -0.489 
(0.086) 
1.10E-08 136624 -0.220 
(0.061) 
3.12E-04 210563 -0.310 
(0.050) 
4.04E-10 347188 4.04E-10 1.16E-10 1.81E-05 
DBP              
rs9710247 (A/G) 
19:40,760,449, AKT2 
0.447 0.252 
(0.051) 
8.11E-07 109695 0.129 
(0.032) 
5.76E-05 198332 0.164 
(0.027) 
1.61E-09 308028 3.82E-02 1.61E-09 5.03E-01 
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Table 2: BP associated SNPs associated with expression of the same gene across 4 or 3 
independent whole-blood eQTL resources and the kidney resource. Signals of association of SNP 
genotype and gene expression in other non-blood tissues in GTEx and in kidney are also indicated. 
Blood dataset order: (i) SABRe, (ii) NESDA-NTR, (iii) BIOS, (iv) GTEx (whole-blood). Top eQTL: Top 
GWAS SNP is top eQTL SNP (or in high LD, r2>0.9, with top eQTL SNP) in at least one data set. eQTL 
signal previously reported: Genes for which eQTL signals have been previously reported for that 
sentinel SNP15-17. For full list, see Supplementary Table 12. 
Sentinel SNP Chr Position Gene Blood 
data sets  
Top 
eQTL 
Signal in 
other 
tissue(s) 
in GTEx 
Signal 
in 
kidne
y 
eQTL 
signal 
previo
usly 
report
ed 
Signal in 4 whole-blood eQTL resources 
rs17367504 1 11862778 CLCN6 YYYY 
 
Y 
 
Y 
rs2169137 1 204497913 MDM4 YYYY Y Y 
 
Y 
rs10926988 1 243483279 SDCCAG8 YYYY 
 
Y 
 
 
rs319690 3 47927484 MAP4 YYYY Y Y 
 
Y 
rs12521868 5 131784393 SLC22A5 YYYY 
 
Y 
 
 
rs900145 11 13293905 ARNTL YYYY 
 
Y 
 
Y 
rs1060105 12 123806219 CDK2AP1 YYYY Y Y Y  
rs1378942 15 75077367 SCAMP2 YYYY 
   
 
rs1126464 16 89704365 CHMP1A YYYY 
 
Y 
 
Y 
rs1126464 16 89704365 FANCA YYYY 
   
Y 
rs12946454 17 43208121 DCAKD YYYY 
 
Y Y Y 
Signal in 3 (out of 4) whole-blood eQTL resources 
rs17367504 1 11862778 MTHFR YYYN 
 
Y 
 
Y 
rs871524 1 38411445 FHL3 NYYY 
 
Y 
 
 
rs871524 1 38411445 SF3A3 NYYY 
 
Y 
 
 
rs4660293 1 40028180 PABPC4 YYYN Y Y 
 
Y 
rs6749447 2 169041386 STK39 YYYN Y 
  
 
rs347591 3 11290122 ATG7 YYYN 
 
Y 
 
 
rs319690 3 47927484 ZNF589 YYNY 
 
Y 
 
 
rs12521868 5 131784393 SLC22A4 YYYN 
 
Y 
 
 
rs1563788 6 43308363 CRIP3 YYYN Y 
  
Y 
rs10943605 6 79655477 PHIP YYYN Y Y 
 
Y 
rs4728142 7 128573967 IRF5 NYYY 
 
Y Y Y 
rs4728142 7 128573967 TNPO3 YYYN 
  
Y  
rs2898290 8 11433909 BLK YYYN 
 
Y 
 
 
rs2898290 8 11433909 FAM167A NYYY 
 
Y 
 
 
rs2898290 8 11433909 FDFT1 YYYN 
 
Y 
 
 
rs2071518 8 120435812 NOV YYYN 
 
Y 
 
 
rs76452347 9 35906471 TPM2 YYYN 
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rs10760117 9 123586737 MEGF9 YYYN 
 
Y 
 
Y 
rs4494250 10 96563757 HELLS YYYN 
   
Y 
rs11191548 10 104846178 NT5C2 YYYN Y 
  
 
rs661348 11 1905292 TNNT3 NYYY 
 
Y 
 
 
rs2649044 11 9763969 SBF2 YYYN 
   
 
rs2649044 11 9763969 SWAP70 YYYN Y Y 
 
? 
rs7129220 11 10350538 ADM YYYN 
   
Y 
rs7103648 11 47461783 MYBPC3 YYYN 
   
 
rs3741378 11 65408937 CTSW YYYN 
   
 
rs7302981 12 50537815 LIMA1 YYYN 
   
Y 
rs7302981 12 50537815 ATF1 YYNY 
 
Y 
 
 
rs1036477 15 48914926 FBN1 YNYY 
   
 
rs1378942 15 75077367 CSK YYYN Y Y 
 
Y 
rs1378942 15 75077367 MPI NYYY 
 
Y 
 
 
rs1378942 15 75077367 ULK3 YNYY 
 
Y 
 
Y 
rs12946454 17 43208121 NMT1 YYYN 
   
Y 
rs2304130 19 19789528 GATAD2A YYYN 
   
 
rs867186 20 33764554 EIF6 NYYY 
 
Y 
 
 
rs6095241 20 47308798 PREX1 YYYN 
   
 
rs9306160 21 45107562 RRP1B YNYY Y Y 
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EGCUT :  Genotyping or analysis: T.E.  Study PI: A.Metspalu   
ARIC :  Genotyping or analysis: D.E.A., A.C.M., P.N.  Study PI: A.Chakravarti   
FHS :  Study phenotyping: D.L.  Genotyping or analysis: S.J.H.  Study PI: D.L.   
MESA :  Study phenotyping: J.I.R.  Genotyping or analysis: W.P., X.G., J.I.R., J.Y.  Study PI: W.P.   
B58C :  Study phenotyping: D.P.S.  Genotyping or analysis: D.P.S.  Study PI: D.P.S.   
COLAUS :  Study phenotyping: P.V.  Genotyping or analysis: M.Bochud, Z.K.  Study PI: P.V.   
PROSPER :  Study phenotyping: J.W.J., D.J.S.  Genotyping or analysis: S.Trompet, J.D.  Study PI: J.W.J.   
BHS :  Study phenotyping: A.James  Genotyping or analysis: N.Shrine, J.H., J.B.   
SHIP :  Study phenotyping: M.D.  Genotyping or analysis: A.T., M.D., U.V.  Study PI: R.R.   
KORA S4 :  Genotyping or analysis: J.S.R.  Study PI: A.Peters   
CHS :  Study phenotyping: B.M.P.  Genotyping or analysis: J.C.B., K.R., K.D.T.  Study PI: B.M.P.   
AGES-Reykjavik :  Genotyping or analysis: A.V.S.  Study PI: V.Gudnason, T.B.H., L.J.L.   
ERF :  Study phenotyping: C.M.v.D., B.A.O.  Genotyping or analysis: N.A.  Study PI: C.M.v.D., B.A.O.   
NESDA :  Study phenotyping: B.W.J.H.P.  Genotyping or analysis: I.M.N., Y.M.  Study PI: H.Snieder, 
B.W.J.H.P.   
YFS :  Study phenotyping: T.L., M.K., O.T.R.  Genotyping or analysis: T.L., L.P.L., M.K., O.T.R.  Study PI: 
T.L., M.K., O.T.R.   
EPIC :  Genotyping or analysis: N.J.W.  Study PI: J.H.Z.   
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ASPS :  Study phenotyping: R.Schmidt  Genotyping or analysis: H.Schmidt, E.H., Y.S., R.Schmidt  Study 
PI: H.Schmidt, R.Schmidt   
ORCADES :  Study phenotyping: J.F.W., H.C., S.W.  Genotyping or analysis: J.F.W., P.K.J., S.W.  Study 
PI: J.F.W.   
FINRISK (COROGENE_CTRL) :  Study phenotyping: P.J.  Genotyping or analysis: K.K., A.P.S.  Study PI: 
M.P., P.J.   
INGI-VB :  Study phenotyping: C.F.S.  Genotyping or analysis: M.T., C.M.B., C.F.S.  Study PI: D.T.   
FINRISK_PREDICT_CVD :  Study phenotyping: V.S., A.S.H.  Study PI: V.S., A.Palotie, S.R.   
TRAILS :  Study phenotyping: H.R.  Genotyping or analysis: P.J.v.d.M.  Study PI: C.A.H., A.J.O.   
PROCARDIS :  Study phenotyping: A.G.  Genotyping or analysis: A.G.  Study PI: H.W., M.Farrall   
HABC :  Study phenotyping: Y.Liu, T.B.H.  Genotyping or analysis: M.A.N.  Study PI: Y.Liu, T.B.H.   
KORA S3 :  Study phenotyping: C.G.  Genotyping or analysis: S.S., C.G., E.O.  Study PI: M.Laan   
INGI-FVG :  Genotyping or analysis: D.V., M.Brumat, M.Cocca  Study PI: P.G.   
Fenland :  Study phenotyping: R.A.S., J.a.L., C.L., N.J.W.  Genotyping or analysis: R.A.S., J.a.L., C.L., 
N.J.W.  Study PI: R.A.S., C.L., N.J.W.   
MICROS :  Genotyping or analysis: A.A.H., F.D.G.M., A.S.P.  Study PI: F.D.G.M., P.P.P.   
HTO :  Study phenotyping: B.D.K.  Genotyping or analysis: B.D.K., K.L.A., C.Mamasoula  Study PI: 
B.D.K., H.J.C.   
MIGEN :  Study phenotyping: R.E., J.Marrugat, S.Kathiresan, D.S.  Genotyping or analysis: R.E., 
S.Kathiresan, D.S.  Study PI: S.Kathiresan   
ULSAM :  Study phenotyping: V.Giedraitis, E.I.  Genotyping or analysis: A.P.M., A.Mahajan  Study PI: 
A.P.M., V.Giedraitis, E.I.   
Cilento study :  Study phenotyping: R.Sorice  Genotyping or analysis: D.R., T.Nutile  Study PI: M.Ciullo   
LBC1936 :  Study phenotyping: I.J.D., A.J.G.  Genotyping or analysis: L.M.L., G.D., A.J.G.  Study PI: 
I.J.D.   
H2000_CTRL :  Study phenotyping: T.Niiranen  Study PI: P.K., A.Jula, S.Koskinen   
NSPHS :  Genotyping or analysis: S.E., Å.J.  Study PI: U.G.   
FUSION :  Genotyping or analysis: A.U.J.  Study PI: J.T., M.Boehnke, F.C.   
GRAPHIC :  Study phenotyping: N.J.S., P.S.B., M.D.T.  Genotyping or analysis: C.P.N., P.S.B., M.D.T.  
Study PI: N.J.S.   
CROATIA_Vis :  Study phenotyping: I.R.  Genotyping or analysis: V.V., J.E.H.  Study PI: V.V., I.R.   
PIVUS :  Study phenotyping: L.Lind, J.S.  Genotyping or analysis: C.M.L., A.Mahajan  Study PI: C.M.L., 
L.Lind, J.S.   
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LOLIPOP :  Study phenotyping: J.S.K., J.C.C.  Genotyping or analysis: J.S.K., W.Z., J.C.C., B.L.  Study PI: 
J.S.K., J.C.C.   
CROATIA_Korcula :  Genotyping or analysis: C.H., J.Marten  Study PI: C.H., A.F.W.   
INGI-CARL :  Study phenotyping: G.G.  Genotyping or analysis: I.G., A.Morgan, A.R.   
LBC1921 :  Study phenotyping: J.M.S., A.Pattie  Genotyping or analysis: J.M.S., S.E.H., D.C.M.L., 
A.Pattie  Study PI: J.M.S.   
CROATIA_SPLIT :  Study phenotyping: O.P., I.K.  Genotyping or analysis: O.P., T.Z.  Study PI: O.P.   
BioMe (formerly IPM) :  Genotyping or analysis: Y.Lu  Study PI: R.J.F.L., E.P.B.  
Replication 
UKB-BP :  Genotyping or analysis: H.R.W., M.R.B., C.P.C., E.E., H.G., B.M., M.R., I.T.  Study PI: P.E., 
M.J.C.   
GoDARTS :  Study phenotyping: C.N.A.P., A.S.F.D.  Genotyping or analysis: C.N.A.P., N.Shah  Study PI: 
C.N.A.P., A.D.M.   
Lifelines :  Study phenotyping: M.H.d.B.  Genotyping or analysis: M.S.  Study PI: P.v.d.H.   
TwinsUK :  Study phenotyping: C.Menni  Genotyping or analysis: M.M., C.Menni  Study PI: T.D.S.   
Airwave Health Monitoring Study :  Genotyping or analysis: A.C.V., E.E., H.G., I.T.  Study PI: E.E.   
The UK Household Longitudinal Study (UKHLS) :  Genotyping or analysis: B.P.P.  Study PI: E.Z.   
Generation Scotland (GS:SFHS) :  Study phenotyping: S.P.  Genotyping or analysis: C.H., A.Campbell   
JUPITER :  Study phenotyping: P.M.R.  Genotyping or analysis: D.I.C., L.M.R., F.G., P.M.R.  Study PI: 
D.I.C., P.M.R.   
NEO :  Study phenotyping: R.d.M.  Genotyping or analysis: D.O.M.K., R.L.G.  Study PI: R.d.M.   
Three City-Dijon :  Study phenotyping: S.D., C.T.  Genotyping or analysis: G.C.  Study PI: S.D., C.T.   
ASCOT-UK :  Study phenotyping: P.S., N.P.  Genotyping or analysis: P.B.M., H.R.W.  Study PI: P.B.M., 
P.S., N.P., M.J.C.   
ASCOT-SC :  Study phenotyping: S.Thom, M.J.C.  Genotyping or analysis: D.C.S., A.S., H.R.W., P.B.M.  
Study PI: S.Thom, M.J.C., P.B.M.   
Hunter Community Study :  Study phenotyping: R.Scott  Genotyping or analysis: C.O., E.G.H.  Study 
PI: A.John   
GAPP :  Study phenotyping: D.C.  Genotyping or analysis: D.C., S.Thériault, G.P.  Study PI: D.C.   
BRIGHT :  Study phenotyping: M.Brown, J.C.  Genotyping or analysis: M.Farrall, P.B.M., H.R.W.  Study 
PI: M.Brown, J.C., M.Farrall, P.B.M., M.J.C.  
Resources for secondary analyses 
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eQTL NESDA NTR :  Design of secondary analysis: R.Jansen  Computation of secondary analysis: 
D.I.B., R.Jansen, B.W.J.H.P.  Study PI: D.I.B., B.W.J.H.P.   
eQTL kidney :  Study phenotyping: J.J.D., M.A.S.  Genotyping or analysis: P.J.v.d.M.  Study PI: 
H.Snieder   
eQTL BIOS :  Design of secondary analysis: R.Jansen  Computation of secondary analysis: R.Jansen  
Study PI: R.Jansen   
SABRe :  Study phenotyping: Y.D., P.J.M., Q.T.N.  Genotyping or analysis: R.Joehanes  Design of 
secondary analysis: D.L.  Study PI: D.L.   
 ICBP-Steering Committee 
G.A., M.J.C., A.Chakravarti, D.I.C., G.B.E., P.E., T.F., M.R.J., A.D.J., M.Larson, D.L., A.P.M., P.B.M., 
C.N.C., P.O.R., W.P., B.M.P., K.R., A.V.S., H.Snieder, M.D.T., C.M.v.D., L.V.W., H.R.W. 
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